From the other side of the consultation, briefly. Start from the measurement rather than the conclusion. Almost every disagreement here turns out to be two people measuring different things and comparing the numbers anyway.

Worth separating that from semaglutide, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

TrialTracker_MD said:

The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the…

Coming at TrialTracker_MD’s question from a different direction. The mechanism that matters here is not stomach emptying, it is central. GLP-1 receptor agonism in the arcuate nucleus stimulates POMC neurons and suppresses AgRP/NPY signalling, which is why the effect is appetite and food salience rather than physical fullness. Delayed gastric emptying largely tachyphylaxes over the first months; the appetite effect does not.

The figures, for anyone assembling their own picture. Worth knowing that the injection site changes very little. Abdomen, thigh and upper arm are bioequivalent for semaglutide, so a site change is not a plausible explanation for a bad week.

That is the short version; the long version is somebody else's post.

Following on from TrialTracker_MD — and this may be the naive question:

How much of the between-person variation is pharmacokinetic and how much is just adherence measured badly?

Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again. Carry on.